PRESS RELEASE published on 11/13/2025 at 17:57, 5 months 25 days ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management pour le compte de CVI Investments, Inc. concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris Euronext Paris Franchissement De Seuils GENSIGHT BIOLOGICS SA Heights Capital Management CVI Investments Inc.
BRIEF published on 10/30/2025 at 07:35, 6 months 10 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 10/30/2025 at 07:35, 6 months 10 days ago GenSight Biologics : Feu vert pour un traitement compassionnel aux États-Unis FDA GenSight Biologics NOHL Accès Compassionnel GS010/LUMEVOQ®
PRESS RELEASE published on 10/30/2025 at 07:30, 6 months 10 days ago Informations privilégiées / Autres communiqués GenSight Biologics a obtenu les autorisations réglementaires pour un traitement compassionnel aux États-Unis avec GS010/LUMEVOQ, visant la Neuropathie Optique Héréditaire de Leber FDA GenSight Biologics Neuropathie Optique Héréditaire De Leber GS010/LUMEVOQ Traitement Compassionnel
BRIEF published on 09/29/2025 at 23:05, 7 months 9 days ago GenSight Biologics annonce ses résultats financiers du premier semestre 2025 Résultats Financiers Recherche Et Développement Trésorerie GenSight Biologics Programmes D'accès Précoce
BRIEF published on 09/29/2025 at 23:05, 7 months 9 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 7 months 9 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie résultats financiers du premier semestre 2025 : gestion optimisée de trésorerie, financement post-clôture, transfert de fabrication, protocole d'étude soumis à l'ANSM Résultats Financiers Financement Trésorerie GenSight Biologics Étude ANSM
PRESS RELEASE published on 09/29/2025 at 23:00, 7 months 9 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 7 months 9 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 8 months 11 days ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
Published on 05/09/2026 at 01:30, 12 hours 50 minutes ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 14 hours 20 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 20:38, 17 hours 42 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 19 hours 8 minutes ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 19 hours 18 minutes ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 1 day 19 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 19 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 19 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 19 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 19 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
